Your browser doesn't support javascript.
loading
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Gavriatopoulou, Maria; Kastritis, Efstathios; Ntanasis-Stathopoulos, Ioannis; Fotiou, Despina; Roussou, Maria; Migkou, Magdalini; Ziogas, Dimitrios C; Kanellias, Nikolaos; Terpos, Evangelos; Dimopoulos, Meletios Athanasios.
Afiliação
  • Gavriatopoulou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Ntanasis-Stathopoulos I; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Fotiou D; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Roussou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Migkou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Ziogas DC; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Kanellias N; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Terpos E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Blood ; 131(4): 464-467, 2018 01 25.
Article em En | MEDLINE | ID: mdl-29167176

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talidomida / Lenalidomida / Fatores Imunológicos / Anticorpos Monoclonais / Mieloma Múltiplo / Antineoplásicos Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talidomida / Lenalidomida / Fatores Imunológicos / Anticorpos Monoclonais / Mieloma Múltiplo / Antineoplásicos Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article